The magnitude of clinical benefit and acceptable safety data in this study confirm the positive benefit:risk ratio of neoadjuvant/adjuvant pertuzumab, trastuzumab, and docetaxel treatment in patients with HER2-positive early or locally advanced breast cancer. The gene discussed is ERBB2; the disease is breast cancer.